Advertisement

Topics

bluebird bio, Inc.  Company Profile

16:12 EDT 25th June 2019 | BioPortfolio


News Articles [184 Associated News Articles listed on BioPortfolio]

BlueBird Intersects 1.33% Ni, 1.26% Cu and 0.10% Co over 4. ...

VANCOUVER, Nov. 29, 2018 /PRNewswire/ - BlueBird Battery Metals Inc. (TSXV: BATT; US: BBBMF) (the "Company" or "BlueBird") is pleased to announce results from the Read more...

Bluebird Bio expands business in N.C.

Bluebird Bio opened a manufacturing facility in Durham, N.C., to produce lentiviral vectors for its gene and cell therapies,  -More- 

EC grants conditional approval for bluebird bio’s Zynteglo

The European Commission (EC) has granted conditional marketing authorisation to bluebird bio’s gene therapy Zynteglo for the treatment of transfusion-dependent...Read More... The post EC grants cond...

Bluebird gene therapy on cusp of European market entry

A nod from an EMA expert panel means Bluebird's LentiGlobin for beta-thalassemia has just one last hurdle before it's cleared.

STAT Plus: Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

Bluebird Bio won’t be selling the world’s most expensive drug. The second priciest? Yup.

Company focus: bluebird bio

Andrew Obenshain, senior vice president and head of Europe at bluebird bio, introduces the company and discusses the challenges and opportunities of gene therapy

Apceth bullish on manufacturing deal with bluebird bio

The German CDMO will operate as commercial manufacturer in Europe for Zynteglo, bluebird bio's first gene therapy to gain regulatory approval

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

NEW YORK, Dec. 5, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised t...

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Co-infections, genetic, and antigenic relatedness of avian influenza H5N8 and H5N1 viruses in domestic and wild birds in Egypt.

A total of 50 poultry farms of commercial broilers (N = 39) and commercial layers (N = 11) suffered from respiratory problems and mortality during the period from January 2016 to December 2017 were in...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy

This is a multi-center, long-term safety and efficacy follow-up study for subjects with hemoglobinopathies (β-thalassemia or severe sickle cell disease) who have been treated with ex vivo...

Companies [4 Associated Companies listed on BioPortfolio]

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

bluebird bio, Inc.

bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gen...

bluebird bio, Inc. 

REVOLUTION Medicines

The REVOLUTION Medicines team brings deep expertise and a track record of building exceptional life sciences companies. In addition to Dr. Goldsmith, founding president and...

More Information about "bluebird bio, Inc. " on BioPortfolio

We have published hundreds of bluebird bio, Inc.  news stories on BioPortfolio along with dozens of bluebird bio, Inc.  Clinical Trials and PubMed Articles about bluebird bio, Inc.  for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of bluebird bio, Inc.  Companies in our database. You can also find out about relevant bluebird bio, Inc.  Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record